Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA(†)

BACKGROUND: We characterized the incidence of central nervous system (CNS) metastases after treatment with trastuzumab emtansine (T-DM1) versus capecitabine–lapatinib (XL), and treatment efficacy among patients with pre-existing CNS metastases in the phase III EMILIA study. PATIENTS AND METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales: Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., Diéras, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679405/
https://www.ncbi.nlm.nih.gov/pubmed/25355722
http://dx.doi.org/10.1093/annonc/mdu486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679405/
https://www.ncbi.nlm.nih.gov/pubmed/25355722
http://dx.doi.org/10.1093/annonc/mdu486

Ejemplares similares